Silence Therapeutics said last week that it has entered into an siRNA drug-delivery collaboration with Japanese drug firm Dainippon Sumitomo Pharma.
Under the terms of the deal, Silence will “demonstrate the functional delivery” of its proprietary siRNA molecules, in combination with its in-house AtuPlex delivery technology, to certain undisclosed targets.
Additional terms of the arrangement, including financial details, were not disclosed.
"Following extensive due diligence in the sector, we have chosen to partner with Silence Therapeutics,” Keiichi Ono, senior executive officer and executive director of drug research division of Dainippon Sumitomo Pharma, said in a statement. “We look forward to expanding this collaboration further in the future.”